1-2 of 2
Candice Jamois
Close
Sort by
Journal Articles

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Clinical Trials & Observations
Marina Y. Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas A. Schäfer, Oliver Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Recher, Rebeca Rodriguez-Veiga, David Taussig, Norbert Vey, Sung-Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M. Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H. Wei
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4147–4156.
https://doi.org/10.1182/bloodadvances.2021006303
Published: 2022
Includes: Supplemental data
Journal Articles

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Clinical Trials & Observations
John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1162–1174.
https://doi.org/10.1182/bloodadvances.2021006043
Published: 2022
Includes: Supplemental data